sign in sign up
<<
Home , Immunosuppressive drug

PHRC 6250 Pharmacodynamics V

CO01: Apply cancer and cancer therapeutics principle CO01.01: Recognize the current cancer incidence in the U.S. CO01.02: Define mutations and oncogens CO01.03: Define the causes of cancer development CO01.04: Recognize the causes of oxidative stress CO01.05: Define the benefits of diets rich in antioxidant CO01.06: Apply antioxidant mechanisms and cancer prevention strategies CO01.07: Recognize different cancer treatment regimens CO01.08: Discuss the differences, uses and benefits of different modes of cancer treatment CO01.09: Identify different classes of anticancer CO01.10: Define the mechanisms of alkylating agents and that are used for cancer treatment CO01.11: Discuss the rational for the different combinations of drugs CO01.12: Describe the possible side effects of the different combination of drugs CO01.13: Define the basic mechanisms of antitumor , and plant alkaloids that are used for cancer treatment CO01.14: Describe the mechanisms and specificity of kinase inhibitors CO01.15: Discuss the combinations of drugs and possible side effects CO01.16: Define biologics and discuss how they work to stop cancer growth CO01.17: Describe the causes and mechanisms of resistance during cancer treatment CO01.18: Discuss the principles of pharmacogenomics as it relates to cancer CO02: Apply the principles of immunopharmacology and therapeutics CO02.01: Describe and distinguish between cell-mediated immunity and CO02.02: State and draw the steps of the complement pathway in humoral immunity CO02.03: Describe the different types of T and B cells and their function in cell-mediated immunity. Draw the decision points in the cell mediate pathway CO02.04: Discriminate presenting cells, and cells types to which presentation occurs CO02.05: Describe cDNA and promoter region of gene CO02.06: Describe transcription factor(s) and how it relates to activation CO02.07: Define how individuals genetic makeup can impact and toxicity CO02.08: Describe and distinguish 4 types of abnormal immune responses CO02.09: Describe the structure and function of an with heavy and light chains and Fc as well as the variable region CO02.10: Apply the principle of antigen-antibody reaction CO02.11: Identify which modulate the differentiation of B cells CO02.12: Distinguish -inhibiting immunosuppressives from proliferation signal inhibitors CO02.13: Organize the hierarchy of drugs with regard to prophyaxis of vs. host disease CO02.14: Organize the hierarchy of drugs with regard to treatment of graft vs. host disease CO02.15: Define teratogenicity CO02.16: List the many toxic effects of including the mot famous toxicity CO02.17: Organize and categorize immunosuppressive drugs according to their metabolism via cytochrome 450 and other enzymes CO02.18: Categorize immunosuppressive drugs in relation to their toxicities CO02.19: Apply mechanisms of action of thalidomide and its immunomodulatory effects CO02.20: Define 3 derivatives of thalidomide and its action CO02.21: Describe the antimetabolic drugs used in autoimmune diseases to achieve cytotoxicity PHRC 6250 Pharmacodynamics V

CO02.22: Discuss non- cytotoxic drugs for autoimmune diseases CO02.23: Describe and biosynthesis CO02.24: Describe and apply the toxicities, clinical uses and mechanisms of action for: , , leflonomide, hydroxychloriquine CO02.25: Describe the principle of hybridoma and its clinical application CO02.26: Describe and compare in detail humanized and chimeric and their production and nomenclature CO02.27: Differentiate the source of antibody with their-suffix name CO02.28: Define the CD-x antibodies with the types of T cells that manifest the specific for them CO02.29: Describe the toxicities, clinical uses and mechanisms of actions for: antilymphocyte antibodies, antithymocyte antibodies, muromonab-CD3, immune globulin intravenous (IGIV), Rho(D) immune globulin microdose, hyperimmune immunoglobulins CO02.30: Describe "blast" cell and the antigen present on blast cell CO02.31: Organize MABs based on the CD antigens CO02.32: Describe MABs based tumor imaging or killing CO02.33: Discuss the pathophysiology of (RA) CO02.34: Describe the various drug classes used in the treatment of RA, class-by-class CO02.35: List & discuss mechanism of action, clinical use, , side effects, contraindications & interactions with other drugs & with each other, of each individual drug class used in RA. CO02.36: Discuss the pathophysiology of the two main autoimmune disorders: systemic erythematosus (SLE) & (MS) CO02.37: Outline and discuss the various classes of immunosuppressive agents used in (graft-versus-host disease, GVHD) & in the autoimmune disorders, class-by- class CO02.38: List and discuss mechanisms of action, clinical uses, pharmacokinetics, aside effects, contraindications and interactions with other drugs and with each other of each one of these immunosuppressive drug classes CO03: Apply the principles of drug associated toxicity CO03.01: Apply the exposure model of drugs and chemicals CO03.02: Describe acute, sub-acute and chronic toxicities, of drugs and chemicals CO03.03: Discuss dose, and duration and route of exposure CO03.04: Discuss the physiological basis of toxicities mediated by: -Reactive oxygen species - Lipid peroxidation -Calcium over load CO03.05: Describe emergency management of poisoned patients CO03.06: Discus the application of for protection of exposed subjects from toxicities associate with chemicals and drugs CO03.07: Describe the toxicities of the following air pollutants: Carbon monoxide Chlorinated hydrocarbon: Carbon tetrachloride, Chloroform, Trichlorethane and Trichloroethene. Aromatic Hydrocarbon toxicity: Benzene, Toluene and Xylene CO03.08: Discuss the treatments, recovery and management of the air pollutants: Nitrogen dioxide, Ozone, Sulpfur dioxide CO03.09: Describe the mechanisms of actions, toxicities, treatment and management of pesticides poising: Organochlorines, Organophosphates, and Carbamtes and Plant pesticides: Paraquat, Chlorophenoxy Herbicides: 2,4-D and 2,4,5-T Polychlorinated biphenyls CO03.10: Describe endocrine disruptors and mode of action of: Bisphenol, Methoxychlor, and DDT metabolites PHRC 6250 Pharmacodynamics V

CO03.11: Describe the principle of Metal Toxicity for protection and treatment of cadmium, lead, arsenic and mercury CO03.12: Describe the toxic syndromes of drugs & use of (s) for management & treatment of: Acetaminophen, Amphetamines, Anticholinergics, SSRI, TCAt, Aspirin, B-blockers, Calcium Channel Blockers CO03.13: Apply the principles of toxicity of: Drugs and toxicants: Choline inhibitors, Cyanide, Digoxin, Ethanol, , Ethylene glycol, and Methanol